Logo image of CYRX

CRYOPORT INC (CYRX) Stock Fundamental Analysis

USA - NASDAQ:CYRX - US2290503075 - Common Stock

8.76 USD
-0.07 (-0.79%)
Last: 11/13/2025, 8:00:01 PM
8.6419 USD
-0.12 (-1.35%)
After Hours: 11/13/2025, 8:00:01 PM
Fundamental Rating

4

Taking everything into account, CYRX scores 4 out of 10 in our fundamental rating. CYRX was compared to 58 industry peers in the Life Sciences Tools & Services industry. The financial health of CYRX is average, but there are quite some concerns on its profitability. CYRX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CYRX was profitable.
In the past year CYRX has reported a negative cash flow from operations.
In the past 5 years CYRX always reported negative net income.
In the past 5 years CYRX reported 4 times negative operating cash flow.
CYRX Yearly Net Income VS EBIT VS OCF VS FCFCYRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

CYRX has a better Return On Assets (8.70%) than 86.21% of its industry peers.
CYRX's Return On Equity of 13.06% is amongst the best of the industry. CYRX outperforms 86.21% of its industry peers.
Industry RankSector Rank
ROA 8.7%
ROE 13.06%
ROIC N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
CYRX Yearly ROA, ROE, ROICCYRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

CYRX's Profit Margin of 33.22% is amongst the best of the industry. CYRX outperforms 100.00% of its industry peers.
CYRX has a Gross Margin (45.73%) which is comparable to the rest of the industry.
CYRX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 33.22%
GM 45.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
CYRX Yearly Profit, Operating, Gross MarginsCYRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CYRX has more shares outstanding
The debt/assets ratio for CYRX has been reduced compared to a year ago.
CYRX Yearly Shares OutstandingCYRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYRX Yearly Total Debt VS Total AssetsCYRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

CYRX has an Altman-Z score of 0.58. This is a bad value and indicates that CYRX is not financially healthy and even has some risk of bankruptcy.
CYRX's Altman-Z score of 0.58 is on the low side compared to the rest of the industry. CYRX is outperformed by 60.34% of its industry peers.
CYRX has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
CYRX has a Debt to Equity ratio of 0.36. This is comparable to the rest of the industry: CYRX outperforms 44.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z 0.58
ROIC/WACCN/A
WACC8.39%
CYRX Yearly LT Debt VS Equity VS FCFCYRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 16.24 indicates that CYRX has no problem at all paying its short term obligations.
CYRX has a Current ratio of 16.24. This is amongst the best in the industry. CYRX outperforms 98.28% of its industry peers.
A Quick Ratio of 15.47 indicates that CYRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 15.47, CYRX belongs to the top of the industry, outperforming 98.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.24
Quick Ratio 15.47
CYRX Yearly Current Assets VS Current LiabilitesCYRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

CYRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 157.07%, which is quite impressive.
CYRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.86%.
Measured over the past years, CYRX shows a very strong growth in Revenue. The Revenue has been growing by 46.45% on average per year.
EPS 1Y (TTM)157.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
Revenue 1Y (TTM)-15.86%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-21.94%

3.2 Future

The Earnings Per Share is expected to grow by 12.23% on average over the next years. This is quite good.
CYRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.14% yearly.
EPS Next Y115.58%
EPS Next 2Y17.38%
EPS Next 3Y13.3%
EPS Next 5Y12.23%
Revenue Next Year-24.8%
Revenue Next 2Y-9.38%
Revenue Next 3Y-3.84%
Revenue Next 5Y0.14%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CYRX Yearly Revenue VS EstimatesCYRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
CYRX Yearly EPS VS EstimatesCYRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.5 -1 -1.5 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 7.49, which indicates a rather cheap valuation of CYRX.
Based on the Price/Earnings ratio, CYRX is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
CYRX is valuated cheaply when we compare the Price/Earnings ratio to 25.91, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for CYRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 7.49
Fwd PE N/A
CYRX Price Earnings VS Forward Price EarningsCYRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYRX Per share dataCYRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

CYRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CYRX's earnings are expected to grow with 13.30% in the coming years.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y17.38%
EPS Next 3Y13.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRYOPORT INC

NASDAQ:CYRX (11/13/2025, 8:00:01 PM)

After market: 8.6419 -0.12 (-1.35%)

8.76

-0.07 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners99.54%
Inst Owner Change-4.24%
Ins Owners4.01%
Ins Owner Change21.62%
Market Cap438.61M
Revenue(TTM)190.26M
Net Income(TTM)67.33M
Analysts85.33
Price Target12.92 (47.49%)
Short Float %6.24%
Short Ratio4.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)484.77%
Min EPS beat(2)12.27%
Max EPS beat(2)957.28%
EPS beat(4)3
Avg EPS beat(4)255.58%
Min EPS beat(4)-40.53%
Max EPS beat(4)957.28%
EPS beat(8)5
Avg EPS beat(8)86.3%
EPS beat(12)6
Avg EPS beat(12)50.61%
EPS beat(16)7
Avg EPS beat(16)31.23%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-5.29%
Max Revenue beat(2)6.79%
Revenue beat(4)1
Avg Revenue beat(4)-0.77%
Min Revenue beat(4)-5.29%
Max Revenue beat(4)6.79%
Revenue beat(8)1
Avg Revenue beat(8)-2.29%
Revenue beat(12)2
Avg Revenue beat(12)-3.23%
Revenue beat(16)3
Avg Revenue beat(16)-2.94%
PT rev (1m)0%
PT rev (3m)17.15%
EPS NQ rev (1m)2.06%
EPS NQ rev (3m)2.57%
EPS NY rev (1m)182.6%
EPS NY rev (3m)119.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.06%
Valuation
Industry RankSector Rank
PE 7.49
Fwd PE N/A
P/S 2.16
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 1.24
EV/EBITDA N/A
EPS(TTM)1.17
EY13.36%
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS4.05
BVpS10.29
TBVpS7.05
PEG (NY)0.06
PEG (5Y)N/A
Graham Number16.46
Profitability
Industry RankSector Rank
ROA 8.7%
ROE 13.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 33.22%
GM 45.73%
FCFM N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
F-Score5
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.5%
Cap/Sales 10.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.24
Quick Ratio 15.47
Altman-Z 0.58
F-Score5
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)112.93%
Cap/Depr(5y)112.05%
Cap/Sales(3y)12.92%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
EPS Next Y115.58%
EPS Next 2Y17.38%
EPS Next 3Y13.3%
EPS Next 5Y12.23%
Revenue 1Y (TTM)-15.86%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-21.94%
Revenue Next Year-24.8%
Revenue Next 2Y-9.38%
Revenue Next 3Y-3.84%
Revenue Next 5Y0.14%
EBIT growth 1Y33.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year96.97%
EBIT Next 3Y28.36%
EBIT Next 5Y18.38%
FCF growth 1Y-17.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-597.62%
OCF growth 3YN/A
OCF growth 5YN/A

CRYOPORT INC / CYRX FAQ

What is the ChartMill fundamental rating of CRYOPORT INC (CYRX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CYRX.


What is the valuation status for CYRX stock?

ChartMill assigns a valuation rating of 4 / 10 to CRYOPORT INC (CYRX). This can be considered as Fairly Valued.


What is the profitability of CYRX stock?

CRYOPORT INC (CYRX) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for CYRX stock?

The Earnings per Share (EPS) of CRYOPORT INC (CYRX) is expected to grow by 115.58% in the next year.